



BSW Formulary Update – December 2022

Prescribing Guidance

- BSW pathway for the [Investigation, treatment and review of Vitamin B12 \(cobalamin\) deficiency](#) has been updated to include revised haematological references ranges for samples processed at SFT. As a reminder, patients can purchase cyanocobalamin 50microgram tablets OTC from a pharmacy in line with [NHSE guidance](#). For any patient with *medically* diagnosed vit B12 deficiency (diet- or non-diet-related) or malabsorption of vit B12 where it is not possible to administer IM hydroxocobalamin, 1mg oral cyanocobalamin (Orobalin®) tablets are a prescription only medicine (POM) and can be issued on FP10. See [SPC](#) and BSW treatment pathway for full guidance.

Other BSWformulary website updates

- The BSW ICB Continuous Glucose Monitoring (CGM) policy has been approved and is available here <https://bsw.icb.nhs.uk/wp-content/uploads/sites/6/2022/12/BSW-ICB-CP052-CGM-Diabetes-Wearable-Technology-for-Adults-Children-living-with-Type-1-Diabetes-1.pdf>
- Additionally, a summary of the different types of CGM that primary care may be asked to prescribe on FP10 is available here [Summary of Intermittent \(isCGM\) and Real-time \(rtCGM\) Continuous Glucose Monitoring Systems available on FP10](#)

New additions to BSWformulary

The following drugs have been added to BSWformulary with RED TLS in line with relevant NICE guidance:

- [Ryeqo® film-coated tablets](#) (40 mg relugolix, 1 mg estradiol (as hemihydrate), and 0.5 mg norethisterone acetate) [Overview | Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids | Guidance | NICE](#)
- [Tavneos® capsules](#) (10mg avacopan) [Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis \(nice.org.uk\)](#)
- [Zeposia® capsules](#) (0.23mg, 0.46mg, 0.92mg ozanimod) [Overview | Ozanimod for treating moderately to severely active ulcerative colitis | Guidance | NICE](#)
- [Brukinsa® capsules](#) (80mg zanubrutinib) [Overview | Zanubrutinib for treating Waldenstrom’s macroglobulinaemia | Guidance | NICE](#)
- [Tavlesse tablets](#) (100mg, 150mg fostamatinib) [Overview | Fostamatinib for treating refractory chronic immune thrombocytopenia | Guidance | NICE](#)

What the BSW ICB formulary team are currently working on

- Reviewing the national NHSE [Shared Care Protocols](#) for implementation locally. The BSW APC has prioritised adoption of these according to existing local protocols (and their date of review) and patient safety factors. Amiodarone and valproate SCAs are identified as BSW priorities.



Bath and North East Somerset,
Swindon and Wiltshire Together

- Working with colleagues in community provider services and urology to build a comprehensive continence products formulary.
- Working with respiratory colleagues to produce local asthma guidance and update the BSW formulary for asthma inhalers.
- Reviewing our local HRT pathway.

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems and Optimise Profiles are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email bswicb.formulary@nhs.net